Almac Announces Expansion of Pharmaceutical Development Facilities
The new formulation development suites will complement Almac’s existing pharmaceutical development facilities and will include high levels of control over environmental conditions as well as extending current capabilities in processing high-potent compounds with OEL’s as low as 0.03μg/m3.
The current GMP development facilities focus on drug products up to pilot scale & registration, whereas, the new facility will operate at lab-scale, with batch sizes for most technologies typically expected to be less than 15 kg scale.
John McQuaid, VP of Technical Operations explains “Almac’s intention is to ensure that there is a seamless transition between development and GMP phases of projects in early stage clinical development. Additionally the scale we have chosen will support the growing area of process DoE studies for candidates in late stage development.”
Phase two of the project will involve a significant expansion of GMP analytical support capabilities with the construction of 2 additional QC laboratories within the new facility.
“The new facilities will effectively double our current pharmaceutical development capacity allowing us to meet the growing demand for our services, both from existing and new clients. Recruitment of experienced formulation and analytical development staff has already commenced in support of this exciting expansion” stated McQuaid.
Phase one of the expansion is due for completion mid 2012 with Phase two of the expansion and configuration of dedicated analytical labs completing towards the end of 2012.
Most read news
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.